losartan has been researched along with Injury, Myocardial Reperfusion in 46 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 7.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 5.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "To produce arrhythmia, the left main coronary artery was occluded for 7 min, followed by 7 min of reperfusion and to produce necrosis, the the left main coronary artery was occluded for 30 min, followed by 120 min of reperfusion." | 5.31 | Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. ( Acet, A; Birincioglu, M; Ozer, MK; Sahna, E, 2002) |
| "The chronic nandrolone treatment impairs the exercise-induced cardioprotection against ischaemia/reperfusion injury by activating the cardiac renin-angiotensin-aldosterone system and downregulating KATP channel expression." | 3.80 | AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion. ( Campos de Carvalho, AC; Ferraz, EB; Marques-Neto, SR; Nascimento, JH; Njaine, B; Rodrigues, DC; Rondinelli, E, 2014) |
| " Blocking the actions of Angiotensin II with an AT1 receptor antagonist (Losartan), has beneficial effects in patients with insulin resistance or type 2 diabetes mellitus." | 3.77 | ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance. ( Friedrich, SO; Huisamen, B; Lochner, A; Pêrel, SJ; Salie, R; Strijdom, H, 2011) |
| "A previous study by our group showed that 10 weeks of pretreatment with losartan reduced myocardial infarct size and arrhythmias in a rat model of ischaemia-reperfusion." | 3.71 | Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor. ( Browne, AE; Chatterjee, K; Lee, RJ; Parmley, WW; Sievers, RE; Sun, Y; Zhu, B, 2001) |
| "To assess the efficacy of losartan (2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphe nyl-4-yl)methyl]imidazole, potassium salt), an angiotensin II receptor antagonist, on acute myocardial ischemia, 36 four-month-old spontaneously hypertensive rats were used." | 3.69 | Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats. ( Ding, YA; Lee, YM; Peng, YY; Yen, MH, 1997) |
| "After selective cardiac arrest with Bretschneider, captopril-treated hearts showed improved hemodynamics compared to control and the other treatment groups." | 1.40 | Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution. ( Dhein, S; Hoyer, A; Kempfert, J; Mohr, FW; Pritzwald-Stegmann, P, 2014) |
| "We evaluated the effects of RU28318 (RU), a selective mineralocorticoid receptor (MR) antagonist, Captopril (Capt), an angiotensin converting enzyme inhibitor, and Losartan (Los), an angiotensin receptor blocker, alone or in combination with ischemia/reperfusion- (I/R-) induced cardiac dysfunction in hearts obtained from normal and diabetic rats." | 1.39 | RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes. ( Akhtar, S; Al-Rashdan, I; Babiker, F; Benter, IF; Yousif, M, 2013) |
| "Leukocyte infiltration and activation in myocardial reperfusion injury may be modulated by nitric oxide synthase isoforms." | 1.33 | Angiotensin II inhibition during myocardial ischemia-reperfusion in dogs: effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity and left ventricular ejection fraction. ( Barros, LF; Becker, C; Carvalho, MH; de Gusmão, FM, 2005) |
| "Losartan can suppress the occurrence of EAD during reperfusion following myocardial ischemia to reduce the incidence of reperfusion arrhythmias, suggesting its protective effect against myocardial ischemic injury." | 1.33 | [Protective effects of losartan against myocardial ischemic reperfusion in intact canine]. ( Chen, YL; Huang, Z; Huo, ZC; Jia, MY; Peng, J; Wang, ZM; Yang, Y, 2005) |
| "ASA, captopril or losartan were given at a concentration of 40 mg/kg/day in drinking water." | 1.32 | Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function. ( Browne, AE; Chatterjee, K; Grossman, W; Karliner, JS; Lee, RJ; Parmley, WW; Sievers, RE; Zhu, BQ, 2003) |
| "Rats treated with losartan had significantly higher levels of angiotensin II in their plasma." | 1.31 | Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. ( Browne, AE; Chatterjee, K; Chou, TM; Lee, RJ; Parmley, WW; Pulukurthy, S; Sievers, RE; Sudhir, K; Sun, Y; Zhu, B, 2000) |
| "We compared the effect of UP (n = 5) and LN (n = 5) on serial in vivo hemodynamics, AngII pressor responses, and left ventricular (LV) volumes and function (echocardiograms) during escalation to optimal oral dosage over 7 days (day 0 to day 6), and acute IR (15 minutes ischemia, 30 minutes reperfusion) and ex vivo AT(1)R protein (Western immunoblots) with additional sham (n = 5) and IR (n = 5) controls on day 6." | 1.31 | Efficacy of pretreatment with the angiotensin II type 1 receptor blocker UP269-6 and losartan in the dog: effect on hemodynamics and ischemia-reperfusion. ( Jugdutt, BI; Menon, V; O'Brien, DW; Xu, Y, 2000) |
| "in Losartan-treated hearts we observed a significant reduction of postischemic contractile dysfunction, CK release and myocardial ultrastructural damage; postischemic FITC-albumin extravasation was significantly reduced respect to controls." | 1.31 | MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. ( Barbacane, RC; Barsotti, A; Conti, P; De Caterina, R; Di Napoli, P; Palka, G; Spina, R; Stuppia, L; Taccardi, AA, 2001) |
| "To produce arrhythmia, the left main coronary artery was occluded for 7 min, followed by 7 min of reperfusion and to produce necrosis, the the left main coronary artery was occluded for 30 min, followed by 120 min of reperfusion." | 1.31 | Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. ( Acet, A; Birincioglu, M; Ozer, MK; Sahna, E, 2002) |
| "Among all treatment groups myocardial infarct size was reduced significantly below saline control only by ramiprilat (-54%) and ramiprilat + angiotensin II (-37%)." | 1.29 | The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors. ( Hartman, JC, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (23.91) | 18.2507 |
| 2000's | 17 (36.96) | 29.6817 |
| 2010's | 17 (36.96) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Djerada, Z | 1 |
| Nuñez, RE | 1 |
| Javadov, S | 2 |
| Escobales, N | 2 |
| Li, Y | 1 |
| Yao, Y | 1 |
| Li, J | 1 |
| Chen, Q | 1 |
| Zhang, L | 1 |
| Wang, QK | 1 |
| Kilic, A | 1 |
| Ustunova, S | 1 |
| Usta, C | 1 |
| Bulut, H | 1 |
| Meral, I | 1 |
| Demirci Tansel, C | 1 |
| Gurel Gurevin, E | 1 |
| Benter, IF | 1 |
| Babiker, F | 1 |
| Al-Rashdan, I | 1 |
| Yousif, M | 1 |
| Akhtar, S | 1 |
| Marques-Neto, SR | 1 |
| Ferraz, EB | 1 |
| Rodrigues, DC | 1 |
| Njaine, B | 1 |
| Rondinelli, E | 1 |
| Campos de Carvalho, AC | 1 |
| Nascimento, JH | 1 |
| Sgarra, L | 1 |
| Leo, V | 1 |
| Addabbo, F | 1 |
| Iacobazzi, D | 1 |
| Carratù, MR | 1 |
| Montagnani, M | 1 |
| Potenza, MA | 1 |
| Hoyer, A | 1 |
| Kempfert, J | 1 |
| Pritzwald-Stegmann, P | 1 |
| Mohr, FW | 1 |
| Dhein, S | 1 |
| Klishadi, MS | 1 |
| Zarei, F | 1 |
| Hejazian, SH | 1 |
| Moradi, A | 1 |
| Hemati, M | 1 |
| Safari, F | 3 |
| Rajtik, T | 1 |
| Carnicka, S | 1 |
| Szobi, A | 1 |
| Giricz, Z | 1 |
| O-Uchi, J | 1 |
| Hassova, V | 1 |
| Svec, P | 1 |
| Ferdinandy, P | 1 |
| Ravingerova, T | 1 |
| Adameova, A | 1 |
| Janic, M | 2 |
| Lunder, M | 2 |
| Cerne, D | 1 |
| Marc, J | 1 |
| Jerin, A | 2 |
| Skitek, M | 2 |
| Drevensek, G | 2 |
| Sabovic, M | 2 |
| Hotta, H | 1 |
| Miura, T | 1 |
| Miki, T | 1 |
| Togashi, N | 1 |
| Maeda, T | 1 |
| Kim, SJ | 1 |
| Tanno, M | 1 |
| Yano, T | 1 |
| Kuno, A | 1 |
| Itoh, T | 1 |
| Satoh, T | 1 |
| Terashima, Y | 1 |
| Ishikawa, S | 1 |
| Shimamoto, K | 1 |
| Huisamen, B | 1 |
| Pêrel, SJ | 1 |
| Friedrich, SO | 1 |
| Salie, R | 1 |
| Strijdom, H | 1 |
| Lochner, A | 1 |
| Parlakpinar, H | 1 |
| Ozer, MK | 2 |
| Acet, A | 2 |
| Hajizadeh, S | 2 |
| Shekarforoush, S | 2 |
| Bayat, G | 2 |
| Foadoddini, M | 1 |
| Khoshbaten, A | 1 |
| Ziberna, L | 1 |
| Hekmatimoghaddam, S | 1 |
| Anvari, Z | 1 |
| Moghadam, MF | 1 |
| Oudot, A | 1 |
| Vergely, C | 1 |
| Ecarnot-Laubriet, A | 1 |
| Rochette, L | 1 |
| Xiao, XH | 1 |
| Allen, DG | 1 |
| Zhu, BQ | 1 |
| Sievers, RE | 3 |
| Browne, AE | 3 |
| Lee, RJ | 3 |
| Chatterjee, K | 3 |
| Grossman, W | 1 |
| Karliner, JS | 1 |
| Parmley, WW | 3 |
| Zhang, D | 1 |
| Yang, L | 1 |
| Liu, Z | 1 |
| Mi, S | 1 |
| Flynn, JD | 1 |
| Akers, WS | 1 |
| Louch, WE | 1 |
| Ferrier, GR | 1 |
| Howlett, SE | 1 |
| de Gusmão, FM | 1 |
| Becker, C | 1 |
| Carvalho, MH | 1 |
| Barros, LF | 1 |
| Yang, Y | 1 |
| Huo, ZC | 1 |
| Peng, J | 1 |
| Jia, MY | 1 |
| Huang, Z | 1 |
| Wang, ZM | 1 |
| Chen, YL | 1 |
| Matsuhisa, S | 1 |
| Otani, H | 1 |
| Okazaki, T | 1 |
| Yamashita, K | 1 |
| Akita, Y | 1 |
| Sato, D | 1 |
| Moriguchi, A | 1 |
| Imamura, H | 1 |
| Iwasaka, T | 1 |
| Hartman, JC | 1 |
| Richard, V | 1 |
| Ghaleh, B | 1 |
| Berdeaux, A | 1 |
| Giudicelli, JF | 1 |
| Lee, YM | 1 |
| Peng, YY | 1 |
| Ding, YA | 1 |
| Yen, MH | 1 |
| Takeda, H | 1 |
| Haneda, T | 1 |
| Kikuchi, K | 1 |
| Mehta, JL | 3 |
| Yang, BC | 2 |
| Phillips, MI | 2 |
| Zhang, YC | 1 |
| Kimura, B | 1 |
| Shen, LP | 1 |
| Mehta, P | 2 |
| Shimizu, M | 1 |
| Sjöquist, PO | 2 |
| Wang, QD | 2 |
| Rydén, L | 1 |
| Zhu, P | 1 |
| Zaugg, CE | 1 |
| Hornstein, PS | 1 |
| Allegrini, PR | 1 |
| Buser, PT | 1 |
| Li, D | 1 |
| Tomson, K | 1 |
| Yang, B | 1 |
| Croker, BP | 1 |
| Zhu, B | 2 |
| Sun, Y | 2 |
| Pulukurthy, S | 1 |
| Sudhir, K | 1 |
| Chou, TM | 1 |
| O'Brien, DW | 1 |
| Xu, Y | 3 |
| Menon, V | 2 |
| Jugdutt, BI | 3 |
| Frolkis, I | 1 |
| Gurevitch, J | 1 |
| Yuhas, Y | 1 |
| Iaina, A | 1 |
| Wollman, Y | 1 |
| Chernichovski, T | 1 |
| Paz, Y | 1 |
| Matsa, M | 1 |
| Pevni, D | 1 |
| Kramer, A | 1 |
| Shapira, I | 1 |
| Mohr, R | 1 |
| Barsotti, A | 1 |
| Di Napoli, P | 1 |
| Taccardi, AA | 1 |
| Spina, R | 1 |
| Stuppia, L | 1 |
| Palka, G | 1 |
| Barbacane, RC | 1 |
| De Caterina, R | 1 |
| Conti, P | 1 |
| Moudgil, R | 1 |
| Musat-Marcu, S | 1 |
| Kumar, D | 2 |
| Dyck, JR | 1 |
| Ford, WR | 1 |
| Clanachan, AS | 1 |
| Lopaschuk, GD | 1 |
| Sahna, E | 1 |
| Birincioglu, M | 1 |
| Fleetwood, G | 1 |
| Boutinet, S | 1 |
| Meier, M | 1 |
| Wood, JM | 1 |
1 review available for losartan and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
The Role of SIRT3 in Mediating Cardioprotective Effects of RAS Inhibition on Cardiac Ischemia-Reperfusion.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cardiotonic Agents; Humans; Losartan; Myocardial Repe | 2015 |
45 other studies available for losartan and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Comparison of the effects of losartan, captopril, angiotensin II type 2 receptor agonist compound 21, and MAS receptor agonist AVE 0991 on myocardial ischemia-reperfusion necrosis in rats.
Topics: Animals; Captopril; Imidazoles; Losartan; Myocardial Infarction; Myocardial Reperfusion Injury; Rats | 2021 |
Critical role of angiotensin II type 2 receptors in the control of mitochondrial and cardiac function in angiotensin II-preconditioned rat hearts.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Heart; Losartan; Male; Mitochondri | 2018 |
Losartan protects against myocardial ischemia and reperfusion injury
Topics: Animals; Antigens, CD; Cadherins; Capillary Permeability; Cells, Cultured; Endothelium, Vascular; He | 2019 |
Angiotensin II type 2 receptor blocker PD123319 has more beneficial effects than losartan on ischemia-reperfusion injury and oxidative damage in isolated rat heart.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Dose-Response Relationship, Drug; Imidazoles; Losa | 2019 |
RU28318, an aldosterone antagonist, in combination with an ACE inhibitor and angiotensin receptor blocker attenuates cardiac dysfunction in diabetes.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diab | 2013 |
AT1 and aldosterone receptors blockade prevents the chronic effect of nandrolone on the exercise-induced cardioprotection in perfused rat heart subjected to ischemia and reperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Heart; KATP Channels; Losartan; Male | 2014 |
Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors.
Topics: Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Bradykinin; Cardiotonic Agents; Heart | 2014 |
Acute hemodynamic effects of angiotensin- converting enzyme inhibition after prolonged cardiac arrest with Bretschneider's solution.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhib | 2014 |
Losartan protects the heart against ischemia reperfusion injury: sirtuin3 involvement.
Topics: Animals; Blotting, Western; Cardiotonic Agents; Catalase; Dose-Response Relationship, Drug; Gene Exp | 2015 |
Oxidative activation of CaMKIIδ in acute myocardial ischemia/reperfusion injury: A role of angiotensin AT1 receptor-NOX2 signaling axis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzylamines; Calcium-Calmodulin-Dependent Protein | 2016 |
The "Rise-Peak-Fall" Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Atorvastatin; Cardiovas | 2016 |
Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic hearts.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcineurin; Diabetes Mellitus, Type 2; Enkephalin | 2010 |
ANG II type I receptor antagonism improved nitric oxide production and enhanced eNOS and PKB/Akt expression in hearts from a rat model of insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiac Output; Diet; In Vitro Techniques; Insulin | 2011 |
Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Blood | 2011 |
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Heart; Heart Rate | 2012 |
Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Biomarkers; Blood P | 2013 |
Expressional profile of cardiac uncoupling protein-2 following myocardial ischemia reperfusion in losartan- and ramiprilat-treated rats.
Topics: Animals; Blood Pressure; Gene Expression Profiling; Heart Rate; Hemodynamics; Ion Channels; Losartan | 2014 |
Angiotensin II activates NADPH oxidase in isolated rat hearts subjected to ischaemia-reperfusion.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Coronary Circulation; Enzyme Activation; Heart; In Vi | 2003 |
The role of endogenous angiotensin II in ischaemia, reperfusion and preconditioning of the isolated rat heart.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Female; In Vitro | 2003 |
Comparative effects of aspirin with ACE inhibitor or angiotensin receptor blocker on myocardial infarction and vascular function.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2003 |
Study on the effects of losartan on cardiomyocyte apoptosis and gene expression after ischemia and reperfusion in vivo in rats.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Female; Gene Expression; Losartan; Male; Myocardial | 2000 |
Effects of the angiotensin II subtype 1 receptor antagonist losartan on functional recovery of isolated rat hearts undergoing global myocardial ischemia-reperfusion.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Heart; Ischemic Preconditioning, Myocardial; Losar | 2003 |
Attentuation of cardiac stunning by losartan in a cellular model of ischemia and reperfusion is accompanied by increased sarcoplasmic reticulum Ca2+ stores and prevention of cytosolic Ca2+ elevation.
Topics: Action Potentials; Animals; Calcium; Cytosol; Guinea Pigs; Heart; Losartan; Membrane Potentials; Mod | 2005 |
Angiotensin II inhibition during myocardial ischemia-reperfusion in dogs: effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity and left ventricular ejection fraction.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Dogs; Hemodynamics; Losartan; Myocardi | 2005 |
[Protective effects of losartan against myocardial ischemic reperfusion in intact canine].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dogs; Electrophysiology; Female; Losartan; Male; M | 2005 |
Angiotensin II type 1 receptor blocker preserves tolerance to ischemia-reperfusion injury in Dahl salt-sensitive rat heart.
Topics: Aldehydes; Amidines; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzylamines; D | 2008 |
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Topics: Adrenergic beta-Antagonists; Amino Acid Oxidoreductases; Angiotensin II; Angiotensin Receptor Antago | 1995 |
Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs.
Topics: Anesthesia; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Coronar | 1993 |
Losartan attenuates myocardial ischemia-induced ventricular arrythmias and reperfusion injury in spontaneously hypertensive rats.
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Ar | 1997 |
Protective effect of the angiotensin-converting enzyme inhibitor captopril on postischemic myocardial damage in perfused rat heart.
Topics: Adenine Nucleotides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Ani | 1997 |
Angiotensin AT1 and AT2 receptor antagonism and myocardial ischemic injury.
Topics: Angiotensin Receptor Antagonists; Animals; Anti-Arrhythmia Agents; Imidazoles; Losartan; Myocardial | 1997 |
Critical role of AT1 receptor expression after ischemia/reperfusion in isolated rat hearts: beneficial effect of antisense oligodeoxynucleotides directed at AT1 receptor mRNA.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; In Vitro Techniques | 1998 |
Effects of the angiotensin AT1 receptor blocker candesartan on myocardial ischemic/reperfusion injury.
Topics: Angiotensin Receptor Antagonists; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Calcium | 1999 |
Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts.
Topics: Adenosine Triphosphate; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enz | 1999 |
Modulation of constitutive nitric oxide synthase, bcl-2 and Fas expression in cultured human coronary endothelial cells exposed to anoxia-reoxygenation and angiotensin II: role of AT1 receptor activation.
Topics: Analysis of Variance; Angiotensin II; Antihypertensive Agents; Apoptosis; Cells, Cultured; Coronary | 1999 |
Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Creat | 1999 |
Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2000 |
Efficacy of pretreatment with the angiotensin II type 1 receptor blocker UP269-6 and losartan in the dog: effect on hemodynamics and ischemia-reperfusion.
Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Dose-Response Relatio | 2000 |
Interaction between paracrine tumor necrosis factor-alpha and paracrine angiotensin II during myocardial ischemia.
Topics: Angiotensin II; Animals; Animals, Newborn; Captopril; Cells, Cultured; Losartan; Male; Myocardial Re | 2001 |
MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia.
Topics: Angiotensin Receptor Antagonists; Animals; Capillary Permeability; Coronary Circulation; Creatine Ki | 2001 |
Postischemic apoptosis and functional recovery after angiotensin II type 1 receptor blockade in isolated working rat hearts.
Topics: Angiotensin Receptor Antagonists; Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase | 2001 |
Effects of different durations of pretreatment with losartan on myocardial infarct size, endothelial function, and vascular endothelial growth factor.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Disease Mode | 2001 |
AT(1) and AT(2) receptor expression and blockade after acute ischemia-reperfusion in isolated working rat hearts.
Topics: Adenosine; Adrenergic alpha-Agonists; Anaerobiosis; Angiotensin-Converting Enzyme Inhibitors; Animal | 2002 |
Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia | 2002 |
Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart.
Topics: Animals; Arrhythmias, Cardiac; Creatine Kinase; Enalaprilat; Imidazoles; In Vitro Techniques; Losart | 1991 |